Johnson & Johnson JNJ

$272.70 -6.00 (-2.15%)

Valuation

Market cap
670,917,376,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.53
P/E (forward)
25.42
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
7,940,500
Avg volume
7,368,556
Day's range
$272.58 – $278.72
Shares out
2,407,310,000
Stochastic %K
29%
Beta
0.22
Analysts
Moderate Buy
Price target
$283.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

meeepah Nov 19, 3:04 PM
$UNH $JNJ safety trade bubble poppin
0 replies
DARKP00L Nov 19, 2:47 PM
$JNJ 08:51 on Nov. 19 2026 Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
0 replies
Wallstfan Nov 19, 2:47 PM
$JNJ added under $267
0 replies
openclassaction2 Nov 19, 1:34 PM
$JNJ 68,029 talc cases were pending in the mdl as of june 1, 2026, per open class actions, with no nationwide settlement and nothing to claim. seems like litigation overhang ignores capex cycles
0 replies
HydrogenH2 Nov 19, 12:56 PM
$JNJ Johnson & Johnson shares fell 2.1% to about $272.75, while a Louisiana appeals court upheld a multimillion-dollar talc-related mesothelioma verdict, keeping litigation risk in focus. The firm has a 50 day moving average of $267.31 and a two-hundred day moving average of $250.38. The stock has a market capitalization of $656.58 billion, a PE ratio of 41.33, a P/E/G ratio of 2.79 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
0 replies
Quantumup Nov 19, 12:28 PM
Guggenheim⬆️ $HELP's PT to $49, reiterated Buy and said--HELP reported positive Phase III APPROACH data for HLP003 in adjunctive MDD, which we view as the strongest dataset yet in this setting. [ $JNJ $CMPS DFTX GHRS STIM ] Guggenheim went on to say: https://x.com/Quantumup1/status/2123392883537461463?a=vcR7NvM81AWhPihgWTE&s=20
0 replies
Nasfact Nov 19, 12:06 PM
$SLS looking forward to first leaking BuOut numbers. Put yourselfs in the role of the CEO. We are all human no matter what. You can only endure so much pressure. - Patient's - Doctors - Shareholders - FDA - crying shorts - Family - Politicians etc.. There was no further LinkedIn post.. No time to sleep or breathe... He does not need any money. Patients need the drug(s) NOW! $MRK $ABBV $JNJ can not risk another desaster bid like the one at $RVMD Will be buying more in a couple of hours.
0 replies
Bobear12 Nov 18, 10:31 PM
$JNJ could MDGL troubling news start to create interest in GALT? What are the chances for fast track approval from the FDA?
0 replies